INSUBCONTINENT EXCLUSIVE:
Independent analyst Kunal Bothra has a buy call on Aurobindo Pharma Ltd
with a target price of Rs 880
The current market price of Aurobindo Pharma Ltd
Time period given by the analyst is Intra Day when Aurobindo Pharma Ltd
price can reach the defined target
Kunal Bothra recommended to keep stoploss at Rs 790
Aurobindo Pharma Ltd., incorporated in 1986, is a largecap company with a market cap of Rs 48264.14 crore.
Aurobindo Pharma Ltd
key Products/Revenue Segments include Pharmaceuticals which contributed Rs 9532.19 Crore to Sales Value (97.45 % of Total Sales), Export
Incentives which contributed Rs 233.20 Crore to Sales Value (2.38 % of Total Sales), Scrap which contributed Rs 8.65 Crore to Sales Value
(0.08 % of Total Sales) and Sale of services which contributed Rs 7.17 Crore to Sales Value (0.07 % of Total Sales)for the year ending
For the quarter ended 30-09-2018, the company has reported a Consolidated sales of Rs 4667.12 Crore, up 11.61 % from last quarter Sales of
Rs 4181.56 Crore and up 7.19 % from last year same quarter Sales of Rs 4354.18 Crore Company has reported net profit after tax of Rs 611.20
The company’s top management includes Dr.M Sivakumaran, Dr.(Mrs.)Avnit Bimal Singh, Mr.K Nithyananda Reddy, Mr.K Ragunathan, Mr.M Madan
Mohan Reddy, Mr.M Sitarama Murthy, Mr.N Govindarajan, Mr.P Sarath Chandra Reddy, Mr.P V Ramprasad Reddy, Mrs.Savita Mahajan
Company has BSR Associates LLP as its auditoRs As on 30-09-2018, the company has a total of 585,907,609 shares outstanding
